The Motley Fool

Two dividend plus growth shares I’d buy and hold for a decade

Image source: Getty Images

Ever since I worked in a business dealing with its products, I’ve liked Smith & Nephew (LSE: SN). The FTSE 100 firm makes replacement joints, with most of its revenues coming from its orthopaedics products. It’s a business that’s led to long-term growth plus dividends.

Smith & Nephew is in a highly regulated industry, and has a range of products that are very well regarded by doctors and patients alike.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

To me, that’s a significant defensive moat. But, probably because of it, the shares can sometimes get a bit pricey. Not this year, though, as the Covid-19 slump has pushed the price down 15%. It’s still ahead of the FTSE 100, mind, with the index down 21%. The dividend provides a relatively low yield, but it’s rising steadily.

A trading update Thursday revealed a 4% revenue drop in the third quarter. That’s a big improvement over the 29.3% fall for the second quarter, and most of the improvement is in orthopaedics. That’s not surprising, as elective surgery pretty much came to a halt round the world with non-essential medical procedures put on hold.

Set for a 2021 comeback?

We’ll get full third-quarter details on 29 October, but for now I think the latest news bodes well. Forecasts suggest a small fall back in the dividend this year. But a rebound in forecasts for 2021 suggest we’ll be back to rising annual income. Yields are relatively low at around 2%. But a progressive dividend can be far more valuable in the long run than a short-term higher yield.

We’re looking at a forecast 2021 price-to-earnings multiple of around 17.5. I think that’s good value for a FTSE 100 stock with long-term growth potential, and paying progressive dividends.

A FTSE 250 dividend

A real estate investment trust (REIT) might not sound like a tempting investment in 2020. But Primary Health Properties (LSE: PHP), in the FTSE 250, is a bit different. The company invests in healthcare properties, primarily GP surgeries, and lets them on long-term leases.

There’s a lot of defensiveness there. Even if commercial real estate in general is under the cosh, demand for healthcare properties is likely to remain solid. And with increasingly ageing populations in the UK and Ireland, I can only see the demand rising.

The Primary Health Properties share price has been one of the most resilient in the FTSE 250 in the face of the pandemic. It dipped relatively lightly in the early lockdown days. And as we enter October, it’s down just 6.5% year-to-date.

What stock market crash?

Analysts don’t really expect any impact on Primary Health’s profits for the full year, which puts it in an enviable position. The dividend has ben rising nicely over the past few years too, and forecasts have that continuing this year and next.

On Thursday, the company confirmed its next quarterly dividend, of 1.475p per share. That’s bang in line with the forecast 5.9p for the full year, which would yield 3.9% on the current share price. I rate it as one of the most reliable dividends in the FTSE 250, and it’s from a stock with long-term growth potential too.

I see Primary Health Properties as a very attractive long-term investment, for a goal of providing steady income in retirement.

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Primary Health Properties. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.